Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin

Completed · Phase 2

Conditions studied: Chronic Hepatitis C

In brief

This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.

Key facts

Study ID

NCT00395421

Run by

Merck Sharp & Dohme LLC

People needed

114

Starts

2006-10-01

Expected to finish

2008-08-01

Last updated by the study team

2010-06-10

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented clinical history compatible with chronic hepatitis C and compensated liver disease
• Has not previously received anti-viral therapy for hepatitis C infection
• Other protocol-defined inclusion criteria may apply.

You may not qualify if…

• Patient is pregnant or breastfeeding
• Patient is co-infected with hepatitis B virus and/or HIV
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Study site — Atlanta, Georgia, United States
• Study site — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.